康希诺公布2024年年报， 报告期内实现营收8.46亿元，同比增加137.01%；实现归母净亏损3.79亿元，同比亏损减少74.45%；实现扣非净亏损4.41亿元，同比亏损减少72.61%。

That hasn’t stopped Bexsero’s steady growth, with sales approaching the $1 billion threshold last year, while Menveo added another ... become a $1 billion to $2 billion product.

The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

此前国内已有四价多糖疫苗获批，然而未覆盖至2岁以下儿童 ... 分别为赛诺菲巴斯德的Menactra、葛兰素史克的Menveo和辉瑞的Nimenrix，但均未在国内 ...